The announcement was based on a new analysis of its clinical trial, which began in July 2020 and enrolled 30,000 U.S. participants.
The new trial data was released just before an Aug. 5 earnings call. In the slides prepared for the call, Moderna said booster shots will most likely become necessary before winter to combat the rapid spread of the delta variant, which became widespread in the U.S. after the trial results were recorded.
“We believe that increased force of infection resulting from delta, non-pharmaceutical intervention fatigue, and seasonal effects (moving indoors) will lead to an increase of breakthrough infections in vaccinated individuals,” the slides read. “While we see durable phase 3 efficacy through six months, we expect neutralizing titers will continue to wane and eventually impact vaccine efficacy. Given this intersection, we believe dose 3 booster will likely be necessary prior to the winter season.”
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
